Optimum chemotherapy for metastatic colorectal cancer

Lancet

Volumn 368, Issue 9552, 2006, Pages 2039-2041

  Bendell, Johanna ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CELECOXIB; DNA TOPOISOMERASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ARTICLE; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INFUSION; HUMAN; INTERMETHOD COMPARISON; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 33845336889     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)69818-8     Document Type: Note

References (11)

1. Grothey A., Sargent D., Goldberg R., and Schmoll H. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22 (2004) 1209-1214
2. Goldberg R., Sargent D., Morton R., et al. Randomized controlled trial of reduced dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 24 (2006) 3347-3353
3. Goldberg R., Sargent D., Morton R., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22 (2004) 23-30
4. Goldberg R., Sargent D., Morton R., Mahoney M., Krook J., and O'Connell M. Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program. J Clin Oncol 20 (2002) 4591-4596
5. de Gramont A., Bosset J., Milan C., et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15 (1997) 808-815
6. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 (2004) 229-237
7. Hochster H., Hart L., Ramanathan R., et al. Results of the TREE 2 cohort: safety, tolerability, and efficacy of bevacizumab added to three oxaliplatin/fluoropyrimidine regimens as first line treatment of metastatic colorectal cancer. abstr 244 (Jan 26-28, 2006), 2006 Gastrointestinal Cancers Symposium, San Francisco, CA, USA. http://www.asco.org/portal/site/ASCO/item.34d60f5624ba07fd506fe310ee37a0 1d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_d etail_view&confID=41&index=y&abstractID=396 (accessed Oct 25, 2006)
8. Fuchs C., Marshall J., Mitchell E., et al. A randomized trial of first-line irinotecan/fluoropyrimidine combination with or without celecoxib in metastatic colorectal cancer (BICC-C). J Clin Oncol 24 suppl (2006) 3506 (abstr)
9. Falcone A., Masi G., Brunetti I., et al. The triplet combination of irinotecan, oxaliplatin, and 5FU/LV (FOLFOXIRI) vs the doublet of irinotecan and 5FU/LV (FOLFIRI) as first-line treatment of metastatic colorectal cancer (MCRC): results of a randomized phase III trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.). J Clin Oncol 24 suppl (2006) 3513 (abstr)
10. Tournigand C., Cervantes A., Figer A., et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 24 (2006) 394-400
11. Maindrault-Goebel F., Lledo G., Chibaudel B., et al. OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study. J Clin Oncol 24 suppl (2006) 3504 (abstr)